Page 901 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

44. MOLÉCULES EN DÉVELOPPEMENT 859

BRIDGES A.J., Chemical inhibitors of protein kinases, Chem. Rev., 2001, 101, 2541-
2571.
COHEN P., Protein kinases-the major drug targets of the twenty-first century ?, Nature
Rev. Drug Discovery, 2002, 1, 309-315.
BOLD G., 1-Anilino-(4-pyridylmethyl)phtalazines as inhibitors of VEGF- and bFGF-indu-
ced angiogenesis, Drugs of the Future, 2002, 27, 43-55.
RAPISARDA A. et al., Identification of small molecule inhibitor of HIF-1 transcriptional
activation pathway, Cancer Res., 2002, 62, 4316-4324.

FARNÉSYLE TRANSFÉRASE
SIROTNAK F.M. et al., A peptidomimetic inhibitor of ras functionality markedly suppres-
ses growth of human prostate tumor xenografts in mice. Prospects for long-term cli-
nical utility, Cancer Chemother. Pharmacol., 2000, 46, 79-83.
ADJEI A.A., Protein famesyl transferase as a target for the development of anticancer
drugs, Drugs of the Future, 2000, 25 (10), 1069-1079.
HALUSKA P. et al., Farnesyl transferase inhibitors as anticancer agents, Eur. J. Cancer,
2002, 38, 1685-1700.
HUNT J.T. et al., Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-
3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS 214662), a fame-
syltransferase inhibitor with potent precllnical antitumor activity, J. Med. Chem., 2000,
43, 3587-3595.
MARTIN C. et al., Synthesis of oxa-bridged analogues of farnesyltransferase inhibitor
RPR 115185, J. Org. Chem., 2001, 66, 3797-3805.

CYCLE CELLULAIRE
SIELECKI T.M. et al., Cyclin-dependent kinase inhibitors : useful targets in cell cycle
regulation, J. Am. Chem. Soc., 2000, 43 (1), 1-14.
OGISO Y. et al., Proteasome inhibition circumvents solid tumor resistance to topoiso-
merase Il-directed drugs, Cancer Res., 2000, 60, 2429-2434.
SHERR C.J., The Pezcoller lecture: cancer cell cycles revisited, Cancer Res., 2000, 60,
3689-3695.
SOON KIM K. et al., Thio-and oxoflavopiridols, cyclin-dependent kinase 1-selective inhi-
bitors: synthesis and biological affects, J. Med. Chem., 2000, 43, 4126-4134.
LAVOIE Retal., Design and synthesis of a novel class of histone deacetylase inhibitors,
Bioorg. Med. Chem. Lett., 2001, 6, 2847-2850.
BRAM SON H.N. et al., Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2) :
design, synthesis, enzymatic activities, and X-ray crystallographic analysis, J. Med.
Chem., 2001, 44, 4339-4358.
ADAMS J., Proteasome inhibition : a novel approach to cancer therapy, Trends in Mole-
cular Medicine, 2002, 8 (4), S49-54.
JOHNSTONE R.W., Histone-deacetylase inhibitors: novel drugs for the treatment of
cancer, Nature Rev. Drug Discovery, 2002, 1, 287-299.